ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-04-30 16:01 |
URD Abivax 2021
|
French | PDF • 3.7 MB | ||
| 2021-04-19 18:11 |
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcera…
|
English | HTML • 10.7 KB | ||
| 2021-04-19 18:00 |
Abivax organise une présentation en webcast sur ABX464 comme traitement potent…
|
French | PDF • 208.4 KB | ||
| 2021-04-16 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 246.6 KB | ||
| 2021-04-14 18:30 |
Abivax termine le traitement du dernier patient de l'étude d'induction de phase…
|
French | PDF • 252.9 KB | ||
| 2021-04-14 18:30 |
Abivax completes induction treatment of last patient in ABX464 phase 2b clinica…
|
English | HTML • 14.4 KB | ||
| 2021-03-31 18:00 |
Abivax : résultats annuels 2020 et point d'avancement sur l'activité
|
French | PDF • 376.4 KB | ||
| 2021-03-31 18:00 |
Abivax reports 2020 financial results and operations update (news with addition…
|
English | HTML • 37.5 KB | ||
| 2021-03-19 18:00 |
ABIVAX: Nombre d'actions composant le capital social et nombre total de droits …
|
French | PDF • 240.3 KB | ||
| 2021-03-05 20:00 |
Abivax se conforme aux recommandations du DSMB d'arrêt de l'étude clinique miR-…
|
French | PDF • 240.7 KB | ||
| 2021-03-05 20:00 |
Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clin…
|
English | HTML • 12.8 KB | ||
| 2021-03-03 18:30 |
Abivax publie dans la prestigieuse revue « Gastroenterology » les résultats de …
|
French | PDF • 224.2 KB | ||
| 2021-03-03 18:30 |
Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ul…
|
English | HTML • 12.9 KB | ||
| 2021-03-01 18:00 |
Abivax nomme le Dr Sophie Biguenet en tant que Directrice Médicale
|
French | PDF • 221.6 KB | ||
| 2021-03-01 18:00 |
Abivax appoints Dr Sophie Biguenet, M.D., as Chief Medical Officer
|
English | HTML • 11.6 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
